Masthead

Leadership

Masthead

Brad Gray President and CEO

Brad has served as a member of the board of directors and as president and chief executive officer of NanoString since June 2010. 

Before joining NanoString, Brad was vice president of Product and Business Development at Genzyme Genetics, the diagnostics division of biotechnology pioneer Genzyme, where he led the development of molecular diagnostics and partnering activities. Before that role, he worked in Genzyme’s Corporate Development group and ran Genzyme Ventures. Prior to Genzyme, Brad was a management consultant in the healthcare practice of McKinsey & Company.

Brad received a BA in Economics and Management from Oxford University, where he studied as a British Marshall Scholar. He also earned an SB in Chemical Engineering from the Massachusetts Institute of Technology.

Tom Bailey Chief Financial Officer

K. Thomas Bailey has served as the chief financial officer of NanoString since January 2018.

Before joining NanoString, Tom was the chief financial officer at AgaMatrix Holdings LLC, a developer, manufacturer, and marketer of medical technologies for diabetes care. Before joining AgaMatrix, he served as chief executive officer and as chief financial officer of Angiotech Pharmaceuticals Inc., a developer, manufacturer, and marketer of local drug, drug delivery, and medical device technologies.

Tom also serves as a director of SCP Interventional Radiology LLC and The Homestretch Foundation and previously served as a director of AgaMatrix Holdings, Angiotech Pharmaceuticals, LifeCare Management Services, and OncoGenex Inc.

Tom received an AB in Economics from Harvard University and an MBA from Harvard Business School.

Joseph M. Beechem, Ph.D. Chief Scientific Officer & Senior Vice President, Research & Development

Joseph M. Beechem, Ph.D., has served as the chief scientific officer and senior vice president of Research and Development at NanoString since April 2012.

Before joining NanoString, Dr. Beechem held various positions at Life Technologies, a publicly traded biotechnology tools company. He most recently served as vice president, head of Advanced Sequencing, and head of Global Sequencing Chemistry, Biochemistry, and Biophysics. During his career at Life Technologies, he led the design and development of multiple genetic analysis technologies, the latest advanced SOLiD sequencing technology, and the single-molecule nano-DNA sequencing technology.

Prior to his industry experience, Dr. Beechem led a National Institute of Health (NIH)-funded research laboratory for 11 years as a tenured associate professor at Vanderbilt University. He has also authored more than 100 peer-reviewed papers in diverse fields such as biomathematics, physics, chemistry, physiology, spectroscopy, diagnostics, and biology. In addition, Dr. Beechem is named on nearly 40 US patents or patent applications and has served on several editorial and scientific advisory boards.

Dr. Beechem received a BS in Chemistry and Biology from Northern Kentucky University and a Ph.D. in Biophysics from Johns Hopkins University.

John D. Gerace Chief Commercial Officer

John joined NanoString as the chief commercial officer in January 2022.

Before joining NanoString, John served as president of DiaSorin Molecular, LLC, the global molecular diagnostics business unit of DiaSorin SpA. Before DiaSorin, John was president and co-founder of Calabri Biosciences LLC, a consulting firm managing a portfolio of mobile healthcare diagnostics and monitoring assets. Prior to that role, he served as president and CEO of Freedom Meditech, an early commercial-stage medical device company that he staged and sold to Trividia Health, a subsidiary of SinoCare, Inc.

John holds BS degrees in Chemistry and Biological Sciences from the University of California at Irvine with honors and an MBA from Pepperdine University. He currently serves on the Board of Directors for the Lacocca Family Foundation, The UC Irvine Foundation, and University Lab Partners.

David W. Ghesquiere Senior Vice President, Corporate and Business Development

David has served as senior vice president, Corporate & Business Development for NanoString since November 2013.

Before joining NanoString, David was the founder and managing director of Adrenaline Venture and Advisory LLC, an international advisory firm. Before founding the advisory firm, David served as senior vice president of Corporate and Business Development at Dendreon Corporation. David has also held various executive positions at OSI Pharmaceuticals, which Astellas Pharma acquired.

David received an MBA from the University of Western Ontario’s Ivey School of Business and a BA in Economics from the University of Western Ontario.

Kathy Surace-Smith Senior Vice President, Human Resources and Legal Affairs

Kathy Surace-Smith has served as senior vice president for NanoString since February 2020.

Before joining NanoString in 2013 as its first general counsel and corporate secretary, Kathy was a legal consultant for various medical technology and global health companies in Seattle, including NanoString. Before that, she was vice president, general counsel, and corporate secretary of  Fujifilm Sonosite Inc., a NASDAQ-listed medical device company specializing in hand-carried ultrasound systems. Prior to Fujifilm Sonosite, Kathy served as vice president, general counsel, and corporate secretary at Metawave Communications, a telecommunications equipment provider.

Kathy received an AB in Politics from Princeton University and a JD from Columbia University School of Law.

Mark A. Winham Senior Vice President, Operations

Mark Winham has served as senior vice president of Operations since October 2019.

Before joining NanoString, Mark served at the C-suite level for Wamberg Genomic Advisors (now Genomic Life), Human Longevity, Inc., and Millennium Health.  Prior to these roles, from 2002 to 2013, Mark worked at senior levels in operations for Applied Biosystems and Life Technologies, including vice president of Global Manufacturing, responsible for the production of various life science instruments and reagents across four continents.

Mark earned his BS in Life Sciences from Napier University in Edinburgh, Scotland.